Clindamycin vaginal cream 2% is a prescription intravaginal medicine used for bacterial vaginosis. The strength refers to the vaginal cream and should not be confused with 1% clindamycin preparations intended for acne. In U.S. pharmacy listings, the exact cream product matters: a standard tube used with multiple applicators is distinct from a prefilled single-dose branded cream.
CDC guidance includes clindamycin 2% vaginal cream among BV regimens, while the individual manufacturer label provides the handling instructions for the actual dispensed package. A cream also has specific considerations for latex condoms and contraceptive diaphragms because certain vehicles contain oil. These are product-level factors, not interchangeable warnings for every vaginal antibiotic.
This guide concentrates on the vaginal cream family, including standard versus single-dose presentation, prescription matching, the role of applicators and safety checks. For a broader view of all formulations, see vaginal clindamycin; for the actual branded single-dose medicine, see Clindesse.
The “2%” designation identifies clindamycin content in the vaginal cream preparation. It does not mean the medicine is the same as topical acne gel, vaginal gel or a suppository measured in milligrams per unit. The intended route is intravaginal, and the written prescription specifies which product presentation and directions apply.
A useful pharmacy description should identify clindamycin phosphate vaginal cream 2%, the type and number of applicators, the quantity and any brand name. Missing details are a reason to ask the dispensing pharmacist questions, not to infer a course from a generic online entry.
| Product question | Standard vaginal cream | Single-dose Clindesse cream |
|---|---|---|
| Concentration | 2% vaginal cream | 2% vaginal cream |
| Presentation | Tube and applicators | One prefilled applicator |
| Treatment instructions | Follow product-specific prescribed course | One labeled application |
| Barrier concern | Oil-based cream and latex warning | Mineral-oil-related warning |
| Do not confuse with | 1% acne cream/gel | 2% Xaciato vaginal gel |
Some clindamycin vaginal creams are provided as a tube with applicators for a prescribed course; the CDC describes a standard cream regimen as part of BV treatment. Clindesse is designed as a single prefilled applicator with its own label. They share the 2% concentration but should not be treated as the same device or instruction set.
One should never calculate a new number of applications merely by comparing percentages. Pharmacy and prescriber must confirm exactly which cream was selected. The single-dose product overview helps distinguish single-application presentations without recommending a swap.
For tube-based cream, confirm the number of applicators and whether the supplied package matches the written order. For a prefilled applicator, identify it explicitly as such; it is not simply an empty device to fill from a standard tube. The patient instructions belong to that particular package.
Patients receiving a delivery should inspect the seal, product name, supplied applicators and readable pharmacy directions. A missing applicator or unexpected pack format is a pharmacy question that should be resolved before use, not fixed using an improvised device.
The oil-based components of certain clindamycin vaginal creams can weaken latex or rubber barrier products. CDC guidance cautions about condoms and diaphragms for five days after using clindamycin cream. Clindesse labeling similarly includes its own five-day barrier precautions.
Because reliable pregnancy and infection prevention may be affected during that interval, ask the clinician or pharmacist about appropriate protection. Do not assume the same warning applies to Xaciato gel, which has a different polyurethane-condom statement. Follow the exact label of the medicine dispensed.
For conventional CLEOCIN vaginal cream, mineral oil can weaken latex or rubber condoms and diaphragms during use and for 72 hours after treatment. CLINDESSE has its own five-day post-dose warning. These two creams are not equivalent merely because both are labeled 2%.
Xaciato is a 2% clindamycin vaginal gel, not a cream. Although both contain clindamycin and may involve an applicator, their vehicles, branded packaging and instructions are distinct. A pharmacy order for cream should not be filled with gel merely because the active ingredient and percentage look similar.
Compare products with the vaginal gel guide and, when a brand is prescribed, the Xaciato brand page. Those resources have their own boundaries and should not be collapsed into this cream-specific discussion.
Vaginal discharge or odor is not enough by itself to establish BV. A clinician may review symptoms and test to rule out other infections or causes of irritation. When clindamycin cream is selected, it addresses that evaluated condition rather than acting as a general vaginal-care product.
CDC treatment guidance offers more than one recommended or alternative regimen. The choice among them can depend on allergies, tolerability, pregnancy and previous therapy. The BV indication guide addresses the decision separately from identifying a cream package.
Vaginal clindamycin cream can cause local symptoms and yeast overgrowth, among other adverse effects. Diarrhea, including potentially serious antibiotic-associated illness, remains a labeled concern. Patients with relevant allergies or prior antibiotic-associated bowel disease should discuss them with the prescriber.
Pregnant patients should not choose a formulation solely from an online product list. CDC guidance recognizes treatment of symptomatic BV in pregnancy while also noting product-specific evidence limitations. Review the actual product label and the obstetric clinician’s assessment before treatment.
Conventional CLEOCIN Vaginal Cream 2% labeling lists hypersensitivity to clindamycin, lincomycin, or formulation components, and histories of regional enteritis, ulcerative colitis, or antibiotic-associated colitis as formal contraindications. Vaginal administration does not remove the possibility of systemic absorption and serious diarrhea. The prescribing clinician must review these restrictions before treatment.
A generic prescription for clindamycin vaginal cream may lead to a particular manufacturer’s 2% cream, while a named brand may refer to a different package presentation. The same concentration does not establish equivalent course instructions, so the label and pharmacy record must be checked together.
Our Cleocin Vaginal Cream and Clindesse pages discuss their respective brand identities. This page stays on cream presentation and applicators rather than recreating those brand histories.
Ask the pharmacist to confirm the exact cream, applicator, labeled instructions, storage and how the package should be handled. Mention any latex barrier contraception needs and ask for the product-specific caution period. Do not copy instructions from an old course or a differently named cream.
If symptoms persist, recur or are accompanied by fever, pelvic pain or abnormal bleeding, contact a clinician rather than purchasing another treatment without assessment. The right product begins with the right diagnosis and prescription.
clindamycin vaginal cream 2% is a prescription vaginal product, not an over-the-counter skin treatment. A pharmacy needs to match the name or authorized generic, exact vaginal form, concentration, applicator configuration and prescriber instructions. The distinction between a cream, gel and ovule is clinically meaningful even when the product name contains clindamycin. See U.S. prescription requirements for the legal access framework.
Match whether the prescription specifies a multi-application tube with disposable applicators or the single-dose prefilled Clindesse presentation; the two cream products must not be conflated. If a pharmacy proposes a different formulation, ask the dispensing pharmacist to contact the prescriber when needed. Consumers should not translate the percentage on one package into an unsupervised dose of another form. The availability verification guide explains how to inquire about a precise product without assuming any pharmacy has current stock.
Oil-based clindamycin vaginal creams may weaken latex condoms and diaphragms. CDC guidance and product labeling caution about an interval after treatment, generally five days for clindamycin vaginal cream formulations discussed here. Confirm the specific brand instructions. Patients should follow the particular package instructions for intercourse, other vaginal products and barrier contraception. These restrictions differ among cream, gel and ovule formulations; advice borrowed from a different clindamycin product can be wrong.
With clindamycin vaginal cream 2%, local administration does not eliminate the risk of antibiotic-associated diarrhea, including potentially serious C. difficile-associated illness. Severe or persistent diarrhea, bloody stools, marked abdominal pain or serious allergic symptoms warrant prompt clinical assessment. New fever, pelvic pain, bleeding or symptoms that do not fit a previously confirmed diagnosis should be assessed rather than repeatedly self-treated.
An applicator tube with multiple doses and a single prefilled cream applicator can differ in price, insurance coverage and quantity; identical “2%” text is not enough to compare bids. Payment varies with the precise brand or generic, applicator package, available supply, formulary coverage and whether the pharmacy can dispense the prescribed presentation. Product cost should never be estimated from a similarly named skin gel or oral capsule; the label and route must match.
Before accepting clindamycin vaginal cream 2%, confirm the vaginal route, concentration, form, number of applicators or units, expiration, storage instructions and any contraceptive-barrier warning. For ways to evaluate payment without unreliable live price quotes, use vaginal clindamycin cost factors.
Yes. Clindamycin vaginal cream requires a valid prescription in the United States.
Both are 2% cream formulations, but Clindesse is supplied as a single-dose prefilled applicator and has its own instructions.
No. Cream and gel differ in formulation, package and product-specific warnings.
No. A prescription vaginal cream is intended for intravaginal use in its labeled indication, not as an acne treatment.
Oil-based creams may weaken latex condoms and diaphragms; review the label and its specified post-treatment interval.
No. Some products use a tube with separate applicators; Clindesse is a prefilled single-dose product.
No. Ovules use a different route-specific dosage form and instructions; medication changes require clinical review.
Vaginal candidiasis or other irritation may occur. Consult a clinician if new symptoms develop.
Confirm the 2% vaginal cream identity, brand or generic, applicator format, quantity and exact directions.